Your browser doesn't support javascript.
loading
Precision-medicine findings from the FACE-SZ cohort to develop motivation-enhancing programs in real-world schizophrenia.
Korchia, Théo; Tastevin, Maud; Sunhary de Verville, Pierre-Louis; Joober, Ridha; Andrieu-Haller, Christelle; Faugere, Mélanie; Godin, Ophélia; Etchecopar-Etchart, Damien; Berna, Fabrice; Aouizerate, Bruno; Capdevielle, Delphine; Chereau, Isabelle; Clauss-Kobayashi, Julie; Coulon, Nathalie; Dorey, Jean-Michel; Dubertret, Caroline; Dubreucq, Julien; Mallet, Jasmina; Misdrahi, David; Passerieux, Christine; Rey, Romain; Schürhoff, Frank; Szoke, Andrei; Urbach, Mathieu; Leboyer, Marion; Llorca, Pierre-Michel; Lançon, Christophe; Richieri, Raphaelle; Boyer, Laurent; Fond, Guillaume.
Afiliação
  • Korchia T; Fondation FondaMental, Créteil, France.
  • Tastevin M; Secteur Timone, EA 327, Faculté de Médecine, CEReSS-Centre d'Etude et de Recherche sur les Services de Santé et la Qualité de vie, AP-HM, Aix-Marseille Université, Marseille, France.
  • Sunhary de Verville PL; Fondation FondaMental, Créteil, France.
  • Joober R; Secteur Timone, EA 327, Faculté de Médecine, CEReSS-Centre d'Etude et de Recherche sur les Services de Santé et la Qualité de vie, AP-HM, Aix-Marseille Université, Marseille, France.
  • Andrieu-Haller C; Secteur Timone, EA 327, Faculté de Médecine, CEReSS-Centre d'Etude et de Recherche sur les Services de Santé et la Qualité de vie, AP-HM, Aix-Marseille Université, Marseille, France.
  • Faugere M; Prevention and Early Intervention Program for Psychosis (PEPP-Montréal), Department of Psychiatry, Douglas Mental Health University Institute, McGill University, Montréal, Canada.
  • Godin O; Fondation FondaMental, Créteil, France.
  • Etchecopar-Etchart D; Secteur Timone, EA 327, Faculté de Médecine, CEReSS-Centre d'Etude et de Recherche sur les Services de Santé et la Qualité de vie, AP-HM, Aix-Marseille Université, Marseille, France.
  • Berna F; Fondation FondaMental, Créteil, France.
  • Aouizerate B; Secteur Timone, EA 327, Faculté de Médecine, CEReSS-Centre d'Etude et de Recherche sur les Services de Santé et la Qualité de vie, AP-HM, Aix-Marseille Université, Marseille, France.
  • Capdevielle D; Fondation FondaMental, Créteil, France.
  • Chereau I; Fondation FondaMental, Créteil, France.
  • Clauss-Kobayashi J; Secteur Timone, EA 327, Faculté de Médecine, CEReSS-Centre d'Etude et de Recherche sur les Services de Santé et la Qualité de vie, AP-HM, Aix-Marseille Université, Marseille, France.
  • Coulon N; Fondation FondaMental, Créteil, France.
  • Dorey JM; INSERM U1114, Fédération de Médecine Translationnelle de Strasbourg, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France.
  • Dubertret C; Fondation FondaMental, Créteil, France.
  • Dubreucq J; Centre Hospitalier Charles Perrens, F-33076 Université de Bordeaux, CNRS UMR 5287-INCIA, Pôle de psychiatrie Générale et Universitaire, Bordeaux, France.
  • Mallet J; INRA, NutriNeuro, University of Bordeaux, Bordeaux, France.
  • Misdrahi D; Fondation FondaMental, Créteil, France.
  • Passerieux C; Service Universitaire de Psychiatrie Adulte, Hôpital la Colombière, CHRU Montpellier, IGF, CNRS, INSERM, Université Montpellier, Montpellier, France.
  • Rey R; Fondation FondaMental, Créteil, France.
  • Schürhoff F; CMP-B, CHU, CNRS, Clermont Auvergne INP, Université Clermont Auvergne, Clermont-Ferrand, France.
  • Szoke A; Fondation FondaMental, Créteil, France.
  • Urbach M; INSERM U1114, Fédération de Médecine Translationnelle de Strasbourg, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France.
  • Leboyer M; Fondation FondaMental, Créteil, France.
  • Llorca PM; Centre Référent de Réhabilitation Psychosociale, CH Alpes Isère, Grenoble, France.
  • Lançon C; Fondation FondaMental, Créteil, France.
  • Richieri R; INSERM U1028, CNRS UMR5292, Centre de Recherche en Neurosciences de Lyon, Université Claude Bernard Lyon 1, Bron Cedex, France.
  • Boyer L; Fondation FondaMental, Créteil, France.
  • Fond G; Department of Psychiatry, Louis Mourier Hospital, Université de Paris, AP-HP, Colombes, Paris, France.
World J Biol Psychiatry ; 23(9): 703-714, 2022 11.
Article em En | MEDLINE | ID: mdl-35057713
ABSTRACT

BACKGROUND:

In people with schizophrenia, major areas of everyday life are impaired, including independent living, productive activities, social relationships and overall quality of life. Enhanced understanding of factors that hinder real-life functioning is vital for treatments to translate into more positive outcomes.

AIM:

The goal of the present study was to identify factors associated with motivation deficits in real-life schizophrenia, and to assess its contribution to impaired functioning and quality of life.

METHODS:

Based on previous literature and clinical experience, several factors were selected and grouped into factors potentially explaining motivation deficits. Some of these variables were never investigated before in relationship with motivation deficits.

RESULTS:

In 561 patients with schizophrenia of the national FACE-SZ cohort living in the community, 235 (41.9%) reported severe motivation deficits. These deficits were found to be significantly associated with impaired socially useful activities, psychological and physical quality of life (in almost all domains), alcohol use disorder (aOR = 2.141, p = 0.021), severe nicotine dependence (aOR = 2.906, p < 0.001) independently of age and sex. No significant association was found for body mass index, metabolic syndrome or physical activity level. In the second model, we identified the following modifiable factors associated with motivation deficits history of suicide attempt (aOR = 2.297, p = 0.001), positive symptoms (aOR = 1.052, p = 0.006), current major depressive episode (aOR = 2.627, p < 0.001), sleep disorders (aOR = 1.474, p = 0.024) and lower medication adherence (aOR = 0.836, p = 0.001) independently of gender, current alcohol use disorder, second-generation antipsychotics and akathisia. No significant association was found for negative symptoms, childhood trauma and inflammation. These results were maintained after removing patients with schizoaffective disorders or those with major depressive disorder.

INTERPRETATION:

Motivation deficits are frequent and remain persistent unmet need in real-world schizophrenia that should be addressed in future guidelines. Based on our results, literature and clinical experience, we recommend to address in priority major depression, sleep, suicide, positive symptoms (when present and as early as possible) and medication adherence to improve motivation deficits of schizophrenia.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esquizofrenia / Transtorno Depressivo Maior / Alcoolismo Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: World J Biol Psychiatry Assunto da revista: PSIQUIATRIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esquizofrenia / Transtorno Depressivo Maior / Alcoolismo Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: World J Biol Psychiatry Assunto da revista: PSIQUIATRIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França